FDA Inspection 1223069 — Anna Gauarashvili
The FDA completed an inspection of Anna Gauarashvili on Nov 2, 2023 in Tbilisi. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 2, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tbilisi (Georgia)
Additional details
Clinical Investigator (CI)